An open-label, multi-center, phase 2 study of chemo-immunotherapy followed by reduced-dose hypofractionated RT and maintenance immunotherapy for stage III unresectable NSCLC

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518408-32-00

Acronym

DEDALUS

Enrollment

Registered

2024-12-03

Start date

Unknown

Completion date

Unknown

Last updated

2024-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Small Cell Lung Cancer

Brief summary

Grade 3 and Grade 4 PRAEs

Detailed description

 Median PFS according to RECIST 1.1 as assessed by the Investigator  PFS6 and PFS12 (12 months) according to RECIST 1.1 as assessed by the Investigator  Median OS and OS12 (12 months)

Interventions

DRUGDURVALUMAB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Grade 3 and Grade 4 PRAEs	—

Secondary

Measure	Time frame
 Median PFS according to RECIST 1.1 as assessed by the Investigator  PFS6 and PFS12 (12 months) according to RECIST 1.1 as assessed by the Investigator  Median OS and OS12 (12 months)	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026